illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Sisram Medical
Company logo

Sisram Medical | Sustainability Performance

https://sisram-medical.com/
Linkedin

Specializes in medical technology and devices. Offers product development, distribution, and support services across aesthetic and therapeutic solutions. Maintains research, clinical partnerships, and regulatory compliance in healthcare operations.

2013

Israel

1,001 - 5,000 employees

Medical Device

$100M - 500M in revenue

$10M - 25M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6842
Overall
#21
in Israel
#107
in Medical Device

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Teva Pharmaceuticals

Israel, Hospital & Health Care, Pharmaceuticals


Company logo
Nano x Imaging

Israel, Hospital & Health Care, Medical Device


Company logo
Taro Pharmaceutical industries

Israel, Hospital & Health Care, Pharmaceuticals

Market cap

117.0M $, 2026▼205.1% YoY

Revenue

349.0M $, 2024▼2.9% YoY

R&D intensity

4.3% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

117.0M $, 2026▼205.1% YoY

Revenue

349.0M $, FY2024▼2.9% YoY

EBITDA

28.0M $, FY2024▼9.1% YoY

Operating margin

8% Industry: -136▼34.7% YoY

Revenue & EBITDA

$349.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

14.9M 2024▼136.8% YoY

Capex

18.0M 2024▲55.6% YoY

Debt/equity ratio

0.1 Industry: 1▼NaN% YoY

R&D intensity

4.3%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

5.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.4

▼ 5.0%

2022

0.4

▼ 9.7%

2023

0.3

▼ 9.4%

2024

0.5

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

40%
Independent Directors

4 out of 10 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email